GILD Gilead Sciences Inc.
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
- 33.46 P/E
- 10.15 P/S
- 10.34 P/B
- 2.7 EPS
- 50.50% Cash ROIC
- 3.94 Cash Ratio
- 0 / 0% Dividend
- 12.34M Avg. Vol.
- 790.12M Shares
- 139.3B Market Cap.
Gilead Sciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for the treatment of life threatening diseases worldwide. Its products include Atripla, Truvada, Viread, Emtriva for the treatment of human immunodeficiency virus infection in adults; Hepsera, an oral formulation for the treatment of chronic hepatitis B; AmBisome, a amph...
Motley Fool - 4 hours ago
Why Gilead Sciences, Inc. (GILD) Is Not Rising Despite Blowout Quarter: Meg ... - Tech Insider
Motley Fool - Jul 22, 2014
Nature World News - 18 hours ago
TheStreet.com - Jul 21, 2014
StreetInsider.com (subscription) - Jul 23, 2014
Seeking Alpha (registration) - 11 hours ago
Seeking Alpha (registration) - 13 hours ago
Bidness Etc - Jul 22, 2014
Seeking Alpha (registration) - 6 hours ago
WKRB News - Jul 23, 2014